| Grant ID | DP220019 |
| Awarded On | February 16, 2022 |
| Title | Development of a 2nd Generation Transducin Beta-like Protein 1 (TBL1) Inhibitor |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Iterion Therapeutics Inc. |
| Principal Investigator/Program Director | Stephen Horrigan |
| Cancer Sites | Leukemia, Lung and Bronchus |
| Contracted Amount | $2,999,995 |
| Lay Summary |
Iterion Therapeutics is a clinical stage biotechnology company headquartered in the Texas Medical Center. Our first drug product, tegavivint, targets the protein TBL1 which interacts with multiple signaling pathways that control cancer cell growth. One of these is the Wnt/beta-catenin pathway which is frequently overactive in cancer. Tegavivint is currently being investigated in a clinical trial for a rare type of sarcoma, desmoid tumors. Early results from this study indicate that the drug is very well tolerated and shows signs of efficacy. Given these promising early results, tegavivint will be investigated in other types of cancer. However, the current formulation of tegavivint requires ... |